Abbott Laboratories
ABT: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$584.00 | Ykdtpgy | Hvplvmttq |
Abbott Well-Poised to Benefit From Nutrition Recovery and New Libre Applications
Business Strategy and Outlook
While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely heavily on its ability to consistently introduce innovative products. On margins, the company has made progress over the last 10 years but still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.